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Abstract Mitochondrial disorders are characterized by a
broad clinical spectrum. Identical clinical signs and symptoms
can be caused by mutations in different mitochondrial or nu-
clear genes. Vice versa, the samemutation can lead to different
phenotypes. Genetic syndromes and neuromuscular disorders
mimicking mitochondrial disorders further complicate the di-
agnostic process. Whole exome sequencing (WES) is the state
of the art next generation sequencing technique to identify
genetic defects in mitochondrial disorders. Until recently it
has mainly been used as a research tool. In this study, the
use ofWES in routine diagnostics is described. TheWES data
of 109 patients, referred under the suspicion of a mitochondri-
al disorder, were examined in two steps. First, the data were
filtered using a virtual gene panel of genes known to be asso-
ciated with mitochondrial disease. If negative, the entire ex-
ome was examined. A molecular diagnosis was achieved in
39 % of the heterogeneous cohort, and in 57 % of the sub-
group of 42 patients with the highest suspicion for a mitochon-
drial disease. In addition to mutations in genes known to be
associated with mitochondrial disorders (e.g. TUFM,
MTFMT, FBXL4), in the subgroup of patients with the lowest
suspicion for a mitochondrial disorder we found mutations in
several genes associated with neuromuscular disorders (e.g.
SEPN1, ACTA1) and genetic syndrome (e.g. SETBP1,
ARID1B). Our results show that WES technology has been
successfully implemented as a state-of-the-art, molecular di-
agnostic test for mitochondrial disorders as well as for the
mimicking disorders in daily clinical practice. It also illus-
trates that clinical and biochemical phenotyping is essential
for successful application of WES to diagnose individual
patients.
Introduction
The clinical spectrum of mitochondrial disorders (MD) is ex-
tremely broad and the underlying biochemical and genetic
defects are heterogeneous (Koopman et al 2012). Identical
clinical signs and symptoms can be caused by mutations in
different mitochondrial or nuclear genes and, vice versa, the
same mutation can lead to different phenotypes. In classical
mitochondrial disorders (MD), the primary biochemical defect
is located in the oxidative phosphorylation system
(OXPHOS). It consists of five multi-subunit enzyme com-
plexes that perform the electron transport of reduction equiv-
alents, generated from the oxidation of mitochondrial sub-
strates, towards molecular oxygen, thereby generating a pro-
ton gradient that drives the phosphorylation of ADP into ATP.
The genes encoding the subunits of these enzymes are distrib-
uted among the mitochondrial DNA (mtDNA) and the nuclear
DNA. Mutations in these genes may result in a defect in the
corresponding subunit, causing an isolated deficiency of one
of the OXPHOS enzymes. In addition, hundreds of different
proteins are required for the biosynthesis of the OXPHOS,
including assembly factors and mitochondrial translation fac-
tors (Mimaki et al 2012; Nouws et al 2012; Smits et al 2010).
A defect in one of these proteins often leads to a deficiency of
OXPHOS enzymes. Furthermore, a large number of defects
outside the OXPHOS have been described that directly or
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indirectly affect the mitochondrial oxidative ATP production,
such as substrate transporters (e.g. SLC25A3,MPC1), proteins
involved in mitochondrial fission and fusion (e.g. OPA1,
MFN2), mtDNA maintenance (e.g. POLG, C10orf2) or mito-
chondrial membrane/phospholipid metabolism (e.g. AGK,
SERAC1). Besides these primary MDs, mitochondrial dys-
function can also be a secondary phenomenon in genetic
syndromes and neuromuscular disorders (Katsetos et al
2013; Valenti et al 2014; Wortmann et al 2009). The
number of nuclear genes currently known to be associated
with MD is more than 250. Novel genetic defects are
discovered at high rate due to the rapidly evolving next
generation sequencing techniques, such as whole exome
sequencing (WES). In the past five years, several papers
have been published in which the application of WES to
MDs has been reported (Ohtake et al 2014; Taylor et al
2014). Most of this work has been done on a research
basis, in particular the studies describing novel genetic
defects (Galmiche et al 2011; Haack et al 2014; Yarham
et al 2014). In addition to these (mainly case) studies,
several papers have described the analysis of selected pa-
tient cohorts, for example of patients with an OXPHOS
enzyme deficiency in fibroblasts or muscle (Calvo et al
2012; Ohtake et al 2014; Taylor et al 2014). The reported
success rates vary between 43 % and 60 %, which is
much higher than the 11 % that is achieved by diagnostic
Sanger sequencing (Neveling et al 2013). The heteroge-
neous phenotypical presentation of patients with MD, the
heterogeneity of underlying genetic defects, and the large
number of proteins involved in the OXPHOS make WES
an excellent, state of the art diagnostic tool for mitochon-
drial disorders. In a proof principle study we have shown
that diagnostic application of WES, using a virtual gene
panel of 211 genes known to be causative for MD for
data filtering, in 44 suspected MD patients had a superior
diagnostic yield when compared to standard Sanger se-
quencing (Neveling et al 2013). Thereafter, our laboratory
has been accredited to use WES as a routine diagnostic
tool for MD (as well as for a number of other genetic
disorders) by the Dutch Accreditation Council. This in-
cluded setting up standard operating procedures, involve-
ment of clinical geneticists, and procedures for unsolicited
findings (Nelen and Veltman 2012; Neveling et al 2013).
Here, we describe the findings in 109 routine diagnostic
WES in patients with a suspected MD. The cohort consists
of both patients seen in Nijmegen and patients seen elsewhere.
Samples from the latter group were sent in by referring phy-
sicians under the suspicion of a mitochondrial disease. The
clinical suspicion for a mitochondrial disease of the patients
varied from relatively low to very high and therefore the co-
hort represents the heterogeneous group of suspected mito-
chondrial patients that are investigated in our diagnostic lab-
oratories in daily practice.
Patients and methods
Patients
WES was performed in 109 pediatric and young adult patients
(up to 27 years of age) under treatment at (or tissues/DNA of
patients sent to) the Nijmegen Centre for Mitochondrial
Disorders (NCMD) between December 2011 and June 2013.
The first 44 patients have also been included in the proof of
principle study in which only a mitochondrial disease gene
panel was investigated. For these patients, the inclusion
criteria were (1) suspicion of a MD by the referring physician,
(2) absence of large scale mtDNA deletions and mtDNA point
mutations (Iontorrent sequencing or GeneChip® Human
Mitochondrial Resequencing Array 2.0 (Affymetrix, Inc);
and long template PCR), (3) absence of copy number varia-
tions (CNV, 250 k SNP array). For many of the remaining 65
patients, these data were also obtained before proceeding to
WES. Written informed consent for WES was obtained after
counselling by a clinical geneticist. The patient cohort is rep-
resentative for the heterogeneous patient population as seen at
the NCMD and its referring centers, showing a broad spec-
trum of clinical signs and symptoms. The most frequently
observed features were intellectual disability, developmental
delay, myopathy/exercise intolerance, and mitochondrial dys-
function in muscle. It is important to highlight again thatWES
was performed as a routine diagnostic test and not in a re-
search setting. Retrospectively, the patient cohort was divided
into three subgroups. The level of suspicion was defined as
Bhigh^, Bintermediate^ or Blow^ by thorough (re-)evaluation
of the available clinical, metabolic, histological, neuroradio-
logical, and biochemical (measurements of the OXPHOS in
fresh muscle and fibroblasts) data of all patients, following the
Nijmegen mitochondrial disease scoring system (Morava et al
2006).
High suspicion of a MD (HS-MD) includes patients with at
least one or more of the following signs and symptoms.
Clinical symptoms suggestive of a MD (e.g. chronic progres-
sive external ophthalmoplegia (CPEO), retinitis pigmentosa,
optic atrophy, myoclonus epilepsy, polyneuropathy); deficien-
cy of one or more enzymes of the respiratory chain in muscle
and cultured fibroblasts; mtDNA depletion in muscle
(mtDNA/nDNA ratio below 30 % of mean reference value);
ragged red fibres and/or COX-negative fibres in muscle; neu-
r o r a d i o l o g i c a l s i g n s o f L e i g h s y n d r om e o r
leukoencephalopathy.
Intermediate suspicion of a MD (IS-MD) includes patients
with a minimum of two out of three of the following signs and
symptoms. Clinical involvement of two or more systems not
being intellectual disability/developmental delay in combina-
tion with exercise intolerance/excessive fatigue; metabolic
evaluation suggestive of a MD (elevated lactate and/or alanine
levels in blood and/or cerebrospinal fluid (CSF)); elevated
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urinary excretion of tricarboxylic acid cycle intermediates or
3-methylglutaconic acid (repeatedly); deficiency of one or
more enzymes of the respiratory chain and/or clearly dimin-
ished ATP-production from pyruvate/malate in a fresh muscle
biopsy.
Low suspicion of a MD (LS-MD) includes all patients with
intellectual disability (isolated or in combination with exercise
intolerance/excessive fatigue without other system involve-
ment), with single system involvement (e.g. isolated cardio-
myopathy), or a reduced ATP-production from pyruvate in
fresh muscle without additional signs and symptoms sugges-
tive for a MD.
Molecular genetics and bioinformatics
WES and the data analysis, including the initial filtering step
using the virtual MD gene panel, were performed essentially
as described before (Neveling et al 2013). An in-house-
developed graphical user interface was applied for data visu-
alization and filtering. For clinical interpretation of variants, a
routine pipeline was applied to predict the mutation impact at
the protein level, which includes data on allele frequency in
various databases (dbSNP, EVS (http://evs.gs.washington.
edu/EVS), and an in-house database), and the prediction tools
SIFT, Polyphen-2 and AlignGVGD (Adzhubei et al 2010; Ng
and Henikoff 2001; Tavtigian et al 2006). In addition, geno-
mic conservation as assessed by PhyloP scoring was included
in the interpretation of variants (Gilissen et al 2012; Pollard
et al 2010). Variants selected in this way, were validated by
Sanger sequencing in the probands, and in family members
where appropriate.
At the time the data of the patients described here were
analysed, the virtual gene panel consisted of 238 genes.
These included the genes known to be associated with MDs
as well as all other genes encoding the structural subunits of
OXPHOS complexes I to V. The panel was designed by a
multidisciplinary expert team consisting of a clinical labora-
tory specialist, a molecular geneticist, and a clinical metabolic
specialist. If no mutations were found in the MD gene panel
(step 1), the entire exome was investigated (step 2). This in-
cluded the analysis of a list of genes encoding proteins with a
mitochondrial localization, or with a function that is
directly linked to mitochondrial function. This list of
genes is composed of publically available gene lists,
such as MitoCarta (Pagliarini et al 2008), and genes
identified in the various research projects in our center.
In addition, the exome was investigated for heterozy-
gous mutations in known genes associated with autoso-
mal dominant disorders, or for homozygous/compound
heterozygous mutations in all other genes. A clinical
report to the referring physician was send after complet-
ing step 1 and, if applicable, after step 2.
Results
The first results of a proof-of-principle study of the implemen-
tation of WES as a diagnostic tool at the RadboudUMC
Nijmegen in 500 patients, including 44 mitochondrial pa-
tients, have been published before (Neveling et al 2013). In
the current report, we describe the results of the follow up
analysis of these patients (in particular those tested negative
for the virtual MD gene panel) and an additional 65 patients
(109 patients in total: 52 females, 57 males, aged 1.8 -27.8,
median 10.8 years). Biochemical investigations of the
OXPHOS in muscle tissue were performed in 92 patients,
and in fibroblasts in 94 patients. In muscle tissue of 80 pa-
tients, a reduced ATP production from pyruvate+malate oxi-
dation was observed. In 29 patients, a deficiency of a single
OXPHOS enzyme was observed, and in 36 patients a com-
bined enzyme deficiency was seen. Single OXPHOS enzyme
deficiencies were found in the fibroblasts of six patients, com-
bined enzyme deficiencies in 15 patients. Based on the clini-
cal, metabolic, histological, neuroradiological and biochemi-
cal data, 42 patients were assigned to the HS-MD group, 44 to
the IS-MD and 23 to the LS-MD group.
A pathogenic mutation explaining the phenotype was
found in 42 patients (39 %, see Table 1 for details). The
highest diagnostic yield was found in the HS-MD group, in
which a genetic diagnosis was made in 24 of 42 patients
(57 %). In 16 of these 42 patients (38 %), a pathogenic muta-
tion in one of the genes included in the MD gene panel was
found. In another eight patients (19 %) a pathogenic mutation
was found outside the MD gene panel. In the IS-MD group of
44 patients, four patients were diagnosed within the MD gene
panel (9 %) and another 6 (14 %) outside the MD gene panel.
The lowest yield for genetically provenMDs was found in the
LS-MD group. In only one of the 23 patients in this group, a
causative mutation within the MD gene panel was found. In
seven patients (30 %) a genetic diagnosis was detected outside
the MD gene panel.
Discussion
In this study, the use ofWES as a routine diagnostic test in 109
patients with a suspected MD has led to a genetic diagnosis in
42 patients (39 %). This is a very satisfactory diagnostic yield
when compared to the diagnostic yield achieved by single
gene Sanger sequencing (11%) in a similar patient population,
before the introduction of WES (Neveling et al 2013). The
diagnostic yield is higher than in previously reported studies
in which gene panels have been selectively sequenced. Lieber
et al reported a diagnostic yield of 22 % sequencing 1600
genes implicated in mitochondrial biology in 102 patients
with suspected MD (Lieber et al 2013). DaRe et al reported
a yield of 9.4 % when investigating 447 genes in 148 patients
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(DaRe et al 2013). The diagnostic yield was the highest in the
subgroup of patients with a high suspicion of a MD (57 %, see
Table 1). In 21 out of 109 patients (19 %), disease causing
mutations were found in one of the genes included in the MD
gene panel. In another 21 patients (19 %), pathogenic muta-
tions were found outside the MD gene panel (Table 1). The
latter includes mutations in genes causing neuromuscular dis-
orders (ACTA1 and SEPN1), as well as genetic syndromes,
such as Kabuki (KDM6A), Schinzel Gideon (SETBP1) and
Coffin-Siris (ARID1B, SMARCA4). Several examples of
non-MD diagnoses established in this way in patients initially
suspected to have a MD have been published before (Davit-
Spraul et al 2013; Lieber et al 2012; McCormick et al 2013;
Monies et al 2014; Nishri et al 2014). In addition, we identi-
fied mutations in genes encoding proteins that are either
known to be localized in mitochondria, or have a function
associated with mitochondrial energy metabolism in five pa-
tients. The details of these findings are outside the scope of the
current article, which is to address the feasibility of WES as
routine clinical diagnostic tool. Diagnosing patients with
clinical features mimicking MD is one of the benefits
of using WES as a diagnostic tool. The genetic variants
identified by WES were evaluated in relation to the
available clinical, metabolic, neuroradiological and bio-
chemical data, by a multidisciplinary team of metabolic
pediatricians, clinical geneticists and laboratory special-
ists. In several cases of our cohort, the diagnosis was
only made after a specific sign or symptom of the pa-
tient was taken into account; three examples follow:
(1) A priori knowledge of the biochemical defect. In the
patient with a GFM1 defect, a heterozygous variant in
GFM1 was present in the WES data. This patient was
known to have a combined respiratory chain enzyme
deficiency of complex I and IV in fibroblasts. The raw
WES data of the GFM1 gene indicated that part of this
gene was not properly covered. Therefore the entire cod-
ing region of this gene was sequenced by Sanger se-
quencing. This led to the identification of a second het-
erozygous mutation, and to the diagnosis.
Table 1 Overview of the results of the exome sequencing in the patient cohort of in total 109 patients
Disease causing mutation found in MD
gene panel; affected genes
Disease causing mutation found outside
MD gene panel; affected genes
Disease causing
mutation found
cumulative
High suspicion of a mitochondrial
disorder HS-MD), N=42
16/42 (38 %); COX15c, 2x TK2a,d, SCO2c,
c12orf65d, NDUFS1a, NDUFS7 a,
SURF1c, COA6 c, 2x FBXL4d,g,
TUFMd, GFM1b, MTFMTd,
NDUFV1 a, MTO1d
8/42 (19 %); SLC3A1/PREPLe
(cystinuria-hypotonia syndrome, MIM #606407),
2x NGLY1a,e (congenital disorder of
deglycosylation, MIM #615273), ARID1Be
(Coffin-Siris syndrome MIM #135900), SCN1Aa
(Dravet syndrome, MIM #607208), unpublished
finding 1, 2,3
24/42 (57 %)
Intermediate suspicion of a
mitochondrial disorder
(IS-MD), N=44
4/44 (9 %); NDUFA1e, RRM2Ba,
RARS2e, SLC25A4d
6/44 (14 %); ASPMe (autosomal rescessive
primary microcephaly5, MIM #608716),
ACTA1a (nemaline myopathy3, MIM # 161800),
ALDH4A1e (hyperprolinemia II, MIM #606811),
RAPSN (congenital myasthenic syndrome with
actylcholine receptor deficiency, MIM #608931),
COL4A1 (susceptibility to intracerebral
hemorrhage, MIM #614519), unpublished
finding 4
10/44 (23 %)
Low suspicion of a mitochondrial
disorder (LS-MD), N=23
1/23 (4 %); MFN2e 7/23 (30 %); CTNNBf mental retardation,
autosomal dominant 19, MIM #615075),
KDM6Ae (Kabuki syndrome 2, MIM#300128),
TBR1e(MIM *604616, (Palumbo et al 2014)),
SMARCA4f (Coffin-Siris syndrome
MIM #135900), SETBP1f (Schinzel-Gideon
midface retraction syndrome, MIM #269150),
SEPN1e (Selenoprotein related myopathy,
MIM #602771), unpublished finding 5
8/23 (35 %)
All patients included, N=109 21/109 (19 %) 21/109 (19 %) 42/109 (38 %)
Overview of the results of the exome sequencing in the patient cohort of in total 109 patients. The names of the genes inwhichmutations have been found
are given. The biochemical diagnosis, based on measurements of mitochondrial ATP production rates, and the activity of the enzyme complexes of the
oxidative phosphorylation system, is indicated as follows: a) complex I deficiency, b) complex III deficiency, c) complex IV deficiency, d) combined
OXPHOS enzyme deficiency, e) reduced ATP production rate but normal OXPHOS enzyme activity, f) normal ATP production and normal OXPHOS
enzymes and g) not determined. In all the cases in which an enzyme deficiency has been observed, the ATP production rate was reduced as well
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(2) A priori knowledge of a specific clinical sign. In a patient
with microcephaly and mitochondrial dysfunction in
muscle no pathogenic mutation was found within the
MD gene panel. By examining the entire exome, in par-
ticular the many genes known to be associated with mi-
crocephaly, led to the finding of mutations in ASPM.
(3) A priori knowledge of metabolic findings. In a patient
with a combined respiratory chain enzyme deficiency in
muscle, but not in fibroblasts, no pathogenic mutation
was detected within in the MD gene panel. A re-
evaluation of the patient, including urinary amino acid
profiling, revealed cystinuria. The raw WES data were
evaluated for copy number variants in the SLC3A1 and
PREPL genes and revealed a homozygous deletion in
this region that could be confirmed by Sanger sequenc-
ing and led to the diagnosis of hypotonia-cystinuria syn-
drome. This multi-exonic deletion was not visible in the
WES variants list. Another cautionary note in this partic-
ular case is that the 250 k SNP array performed prior to
WES, failed to identify this micro-deletion/continuous
gene syndrome. These examples illustrate that WES en-
ables us to establish a diagnosis in a phenotypically di-
verse group in which it is often very difficult to discrim-
inate between MD and mimicking disorders. It also un-
derlines that successful application of WES depends on
accurate phenotyping.
Currently, the strategies for next generation sequencing of
patients with a suspected MD can be divided into two funda-
mentally different approaches: WES and targeted gene panel
sequencing. The pros and cons of these approaches with re-
spect to the application to MD patients have been reviewed
recently (Carroll et al 2014). In our opinion, the approach used
at the RadboudUMC Nijmegen as described here, combines
the advantages of both methods: (1) WES can be used as a
generic approach for almost any group of genetic disorders,
which is cost-effective as all patients can be examined follow-
ing the same pipeline. (2) The data can be re-investigated in
the future, for example when improved methods for data han-
dling and annotation have been developed, or when Bnew^
genes involved in MD have been discovered. (3) Although
WES data interpretation is more complicated and time con-
suming data in comparison to targeted gene panel sequencing,
the use of virtual gene panels to filter the WES data narrows
down the number of genetic variants that initially need to be
interpreted. (4) If no mutations are detected in the virtual gene
panel, the data can be re-evaluated by filtering the data using
other gene panels (e.g. neuromuscular disorders) or by a com-
plete exome analysis. This is of special importance given the
phenotypic overlap of MD with other metabolic disorders,
neuromuscular disorders and genetic syndromes (Briones
et al 2001). A disadvantage ofWES is that targeted gene panel
sequencing gives a higher coverage, although the coverage of
WES is continuously being increased. Nevertheless, in the
case of a strong suspicion for a mutation in a single or very
few genes, targeted sequencing of these candidate genes may
be preferred over WES.
Continuous technological innovations have led to reduced
costs, shorter turn-around times and increased quality ofWES,
and it is expected that this trend will continue in the future. As
a consequence, WES is increasingly used at an early stage of
the diagnostic work-up of suspected mitochondrial patients,
before the invasive procedure of a muscle biopsy is consid-
ered. However, as our data show, the interpretation of WES
data may be compromised by a lack of information on the
clinical and biochemical phenotype of the patient.
Furthermore, the finding of unknown variants of uncertain
pathogenicity in genes not earlier reported to lead to MD will
need functional validation in muscle or fibroblasts. Even var-
iants in known disease genes may require functional valida-
tion, e.g. in the case of an unusual clinical presentation. This
validation may consist of a relatively simple test, such as a
Western blot or a specific enzyme assay, e.g. measuring com-
plex I activity. A more reliable confirmation of pathogenicity
could be obtained by genetic complementation studies, in
which the wild type gene is introduced in cultured patient cells
to test if this restores the cellular or biochemical defect. It has
been demonstrated before that this strategy is particularly suit-
able for genetic defects causing mitochondrial disorders
(Danhauser et al 2011; Huigsloot et al 2011; Jonckheere
et al 2013). Until now, tests like these are being performed
in a research setting, but technological innovations may allow
for a diagnostic application in the future. As a significant
number of MD patients are carriers of pathogenic mtDNA
mutations, it is important to note that mtDNA sequencing in
clinically affected tissue should be performed prior to WES.
Based on our experiences using WES on patients with
varying degrees of suspicion for a MD, we would like to make
the following recommendations for the laboratory diagnostic
tests to be performed. As described above, WES data analysis
benefits from detailed knowledge on the biochemical and clin-
ical phenotype. Therefore, in patients with a high suspicion of
a MD, we would advise to start the work up with a muscle and
skin biopsy for mitochondrial enzyme measurements and
mtDNA sequencing, before performing WES. Should a mus-
cle biopsy for whatever reason not be possible and it is decid-
ed to start with WES as a first diagnostic test, we recommend
to simultaneously prepare a skin fibroblasts culture for
OXPHOS enzyme analysis. This will provide valuable infor-
mation for the WES data analysis, and the fibroblasts can also
be used for the functional validation of genetic variants iden-
tified by WES.
Of the genetic defects found outside the MD gene panel,
seven genetic defects were found in genes present in the intel-
lectual disability gene panel (ARID1B, SCN1A, ASPM,
CTNNB, KDM6A, SMARCA4 and SETBP1). Therefore, in
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patients with intellectual disability and a medium or low sus-
picion of a MD, we would advise to perform WES using the
virtual gene panels for MD and intellectual disability. The
latter panel contains more than 500 genes known to be asso-
ciated with intellectual disability (de Ligt et al 2012).
Additionally a so called TRIO approach including WES anal-
ysis of both parents could be considered, allowing the detec-
tion of de novo autosomal dominant mutations causing intel-
lectual disability (Vissers et al 2010). Should these approaches
not be successful, the next step is likely to be whole genome
sequencing, which will be the next step in molecular diagnos-
tic and that has already been shown to have a higher success
rate than WES (Gilissen et al 2014).
Taken together, WES technology has been successfully im-
plemented as a routine, state of the art diagnostic test forMD and
genetic disorders mimicking MDs. The interpretation of the
WES data benefits from knowledge on the clinical, metabolic,
neuroradiological and biochemical phenotype, and a thorough
evaluation of the data by a multi-disciplinary team.
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